Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 29, 2017 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa

Key Updates ProQR’s drug candidate, QR-313 for dystrophic epidermolysis bullosa (DEB) receives orphan drug designation in the EU from the EMA.QR-313 also received U.S. ODD from the FDA in September...
November 21, 2017 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR to Present at the Annual Piper Jaffray Healthcare Conference

LEIDEN, the Netherlands, Nov. 21, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.(Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
November 20, 2017 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Results for the Third Quarter of 2017

Key updates Runway into the second half of 2019: cash of €39.7 million at end of Q3, increased by gross proceeds of approximately $20 million from an issuance of ordinary shares in November 2017 that...
November 14, 2017 07:44 ET | Source: ProQR Therapeutics N.V.

ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares

LEIDEN, The Netherlands, Nov. 14, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA...
November 13, 2017 16:01 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Proposed Public Offering of Ordinary Shares

LEIDEN, the Netherlands, Nov. 13, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA...
November 13, 2017 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness

Key Updates The first patient has received the first dose of QR-110 in the Phase 1/2 safety & efficacy clinical trial (PQ-110-001: NCT03140969) in children and adults with Leber’s congenital...
November 09, 2017 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board

Key Updates Dr. Thaddeus (Ted) Dryja, a pioneer in the field of retinal genetic diseases, joins the Company’s Scientific Advisory Board.Dr. Dryja will play a key strategic role in the development and...
October 31, 2017 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR to Present at EuroTIDES Conference

LEIDEN, The Netherlands, Oct. 31, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
October 26, 2017 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Management Change and Key Promotions

Key Updates Company announces departure of Noreen R. Henig, Chief Medical Officer, promotion of Peter Adamson to Senior Vice President Ophthalmology Franchise and Robert Friesen to Senior Vice...
October 24, 2017 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference

LEIDEN, the Netherlands, Oct. 24, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...